Amgen Announces New Data From Phase 2 BLINCYTO Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease /PRNewswire/ -- Amgen today announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager immunotherapy BLINCYTO in patients with minimal residual disease positive B-cell precursor acute lymphoblastic leukemia . In the study, 78 percent of patients who received BLINCYTO experienced a complete MRD response , a measure of eradication of residual disease at the molecular level, after one treatment cycle.
http://ift.tt/1wSv9bg
http://ift.tt/1wSv9bg
No comments:
Post a Comment